cb-010,fludarabine,cyclophosphamide
Caribou Biosciences
['car-t']
we are excited to share additional data from our antler phase 1 #clinicaltrial today at #eha2022, showing cb-010 as the 1st allogeneic car-t #celltherapy to achieve a 100% cr rate as best response for all 6 patients. to learn more, watch our webcast here: 
Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases